<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00575380</url>
  </required_header>
  <id_info>
    <org_study_id>041-103</org_study_id>
    <secondary_id>P08655</secondary_id>
    <nct_id>NCT00575380</nct_id>
  </id_info>
  <brief_title>Study of AzaSite Versus Vigamox Concentrations in the Conjunctiva and Aqueous Humor in Subjects Undergoing Routine Cataract Surgery</brief_title>
  <official_title>A Multi-Center, Open-Label, Randomized Study of the Pharmacokinetics of Azithromycin Versus Moxifloxacin in Conjunctiva and Aqueous Humor Following Single or Multiple Ocular Administration of AzaSite Ophthalmic Solution, 1% or Vigamox in Subjects Undergoing Routine Cataract Surgery</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Merck Sharp &amp; Dohme Corp.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the drug concentrations in the conjunctiva and
      aqueous humor of AzaSite™ compared to Vigamox® in subjects undergoing routine cataract
      surgery
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>December 2007</start_date>
  <primary_completion_date type="Actual">June 2008</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Conjunctiva Concentration Prior to Cataract Surgery at One of Ten Time Points Ranging From 1 to 14 Days (Per Protocol Pharmacokinetic Population)</measure>
    <time_frame>Az(hr): 1,12,48,49,72,144,145,168,216,312; Vig(hr): 1,8,48,49,56,144,145,168,216,312</time_frame>
    <description>Nominal time is scheduled time relative to administration of the first eye drop</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Aqueous Humor Concentration Prior to Cataract Surgery at One of Ten Time Points Ranging From 1 to 14 Days (Per Protocol Pharmacokinetic Population)</measure>
    <time_frame>Az(hr): 1,12,48,49,72,144,145,168,216,312; Vig(hr): 1,8,48,49,56,144,145,168,216,312</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">116</enrollment>
  <condition>Bacterial Infections</condition>
  <condition>Eye Infections</condition>
  <condition>Cataract Extraction</condition>
  <arm_group>
    <arm_group_label>AzaSite Eye Drops</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>One drop two times a day for two days and once a day for the next five days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Vigamox Eye Drops</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>One drop three times a day for seven days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AzaSite Eye Drops</intervention_name>
    <description>One drop two times a day for two days and once a day for the next five days.</description>
    <arm_group_label>AzaSite Eye Drops</arm_group_label>
    <other_name>AzaSite (azithromycin ophthalmic solution)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vigamox Eye Drops</intervention_name>
    <description>One drop three times a day for seven days</description>
    <arm_group_label>Vigamox Eye Drops</arm_group_label>
    <other_name>Vigamox(moxifloxacin hydrochloride ophthalmic solution)</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Are scheduled to undergo routine cataract surgery by the investigator's preferred
             technique.

          -  Have normal appearing, freely mobile, conjunctiva in the inferior temporal portion
             cul-de-sac site of the operative eye.

        Exclusion Criteria:

          -  Have concurrent infectious/noninfectious conjunctivitis, keratitis or uveitis in
             either eye.

          -  Have a history of ocular pemphigoid.

          -  Have ever had penetrating ocular surface surgery.

          -  Have had intraocular surgery within the past 3 months.

          -  Have ever had prior surgery or full penetrating trauma to the conjunctiva at the
             proposed surgical site.

          -  Have a planned cataract surgery in the contraleteral eye within 2 weeks of the study
             related surgical procedure and sample collection.

          -  Have a combined procedure planned (trabeculectomy surgery planned in the same eye as
             cataract extraction surgery).

          -  Have at the proposed conjunctiva biopsy site, signs of conjunctival shortening of the
             fornix, scarring or adherence to the underlying episclera.

          -  Have according to the investigator's judgment, risk of intra- or post-operative
             complications related to their cataract surgery as a consequence of participation in
             the study.

          -  Have a known hypersensitivity to azithromycin, or any macrolide antibiotic or to any
             of the ingredients in AzaSite.

          -  Have had a known hypersensitivity to Vigamox or any fluoroquinolone antibiotics or to
             any of the ingredients in Vigamox.

          -  Are unable or unwilling to withhold for a minimum of 3 weeks prior to initiation of
             study drug, the ocular or systemic use of either azithromycin or moxifloxacin, when it
             is the same medication as the subject's assigned study drug. This relates as well, to
             the use of either of these medications as a pre-surgical prophylaxis.

          -  Are unable or unwilling to withhold for a minimum of 3 weeks prior to initiation of
             study drug, the use of erythromycin ointment or ofloxacin.

          -  Have any ocular pathology with the exception of cataracts that in the judgment of the
             investigator could confound study assessments or limit compliance.

          -  Have a serious systemic disease or uncontrolled medical condition or psychiatric
             condition that in the judgement of the investigator could confound study assessments
             or limit compliance.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Reza Haque, MD</last_name>
    <role>Study Director</role>
    <affiliation>Merck Sharp &amp; Dohme Corp.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Cornea Consultants of Arizone</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85032</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Eye Care Arkansas</name>
      <address>
        <city>Little Rock</city>
        <state>Arkansas</state>
        <zip>72205</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>North Valley Eye Medical Group</name>
      <address>
        <city>Mission Hills</city>
        <state>California</state>
        <zip>91345</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Center for Excellence in Eye Care</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33176</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Eye Center of North Florida</name>
      <address>
        <city>Panama City</city>
        <state>Florida</state>
        <zip>32405</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Coastal Research Associates, LLC</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30339</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kentuckiana Institute for Eye Research</name>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <zip>40207</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ophthalmology Associates</name>
      <address>
        <city>St. Louis</city>
        <state>Missouri</state>
        <zip>63131</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ophthalmic Consultants of Long Island</name>
      <address>
        <city>Rockville Centre</city>
        <state>New York</state>
        <zip>11563</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Eye Care Specialists</name>
      <address>
        <city>Kingston</city>
        <state>Pennsylvania</state>
        <zip>18704</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical University of South Carolina</name>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <zip>29464</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Glaucoma Consultants and Center for Eye Research</name>
      <address>
        <city>Mount Pleasant</city>
        <state>South Carolina</state>
        <zip>29464</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Corona Research Consultants</name>
      <address>
        <city>El Paso</city>
        <state>Texas</state>
        <zip>79904</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 12, 2007</study_first_submitted>
  <study_first_submitted_qc>December 14, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 18, 2007</study_first_posted>
  <results_first_submitted>June 9, 2009</results_first_submitted>
  <results_first_submitted_qc>August 11, 2009</results_first_submitted_qc>
  <results_first_posted type="Estimate">September 16, 2009</results_first_posted>
  <last_update_submitted>September 20, 2011</last_update_submitted>
  <last_update_submitted_qc>September 20, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 22, 2011</last_update_posted>
  <responsible_party>
    <name_title>Mike Schiewe</name_title>
    <organization>Inspire Pharmaceuticals</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infection</mesh_term>
    <mesh_term>Communicable Diseases</mesh_term>
    <mesh_term>Cataract</mesh_term>
    <mesh_term>Bacterial Infections</mesh_term>
    <mesh_term>Eye Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tetrahydrozoline</mesh_term>
    <mesh_term>Pharmaceutical Solutions</mesh_term>
    <mesh_term>Ophthalmic Solutions</mesh_term>
    <mesh_term>Moxifloxacin</mesh_term>
    <mesh_term>Fluoroquinolones</mesh_term>
    <mesh_term>Azithromycin</mesh_term>
    <mesh_term>Norgestimate, ethinyl estradiol drug combination</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Azasite</title>
        </group>
        <group group_id="P2">
          <title>Vigamox</title>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="58"/>
                <participants group_id="P2" count="58"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="57"/>
                <participants group_id="P2" count="55"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Various</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Azasite</title>
        </group>
        <group group_id="B2">
          <title>Vigamox</title>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="58"/>
            <count group_id="B2" value="58"/>
            <count group_id="B3" value="116"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="71.0" spread="7.57"/>
                    <measurement group_id="B2" value="66.3" spread="10.02"/>
                    <measurement group_id="B3" value="68.6" spread="9.15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="34"/>
                    <measurement group_id="B2" value="28"/>
                    <measurement group_id="B3" value="62"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="24"/>
                    <measurement group_id="B2" value="30"/>
                    <measurement group_id="B3" value="54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Conjunctiva Concentration Prior to Cataract Surgery at One of Ten Time Points Ranging From 1 to 14 Days (Per Protocol Pharmacokinetic Population)</title>
        <description>Nominal time is scheduled time relative to administration of the first eye drop</description>
        <time_frame>Az(hr): 1,12,48,49,72,144,145,168,216,312; Vig(hr): 1,8,48,49,56,144,145,168,216,312</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Azasite</title>
          </group>
          <group group_id="O2">
            <title>Vigamox</title>
          </group>
        </group_list>
        <measure>
          <title>Conjunctiva Concentration Prior to Cataract Surgery at One of Ten Time Points Ranging From 1 to 14 Days (Per Protocol Pharmacokinetic Population)</title>
          <description>Nominal time is scheduled time relative to administration of the first eye drop</description>
          <units>ug/g</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="57"/>
                <count group_id="O2" value="55"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Timepoint 1 - 1 hr (AzaSite and Vigamox)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="40.4" spread="19.7752"/>
                    <measurement group_id="O2" value="5.747" spread="3.4775"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Timepoint 2 - 12 hrs (AzaSite)/8 hrs (Vigamox)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="33.55" spread="11.81"/>
                    <measurement group_id="O2" value="1.051" spread=".8099"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Timepoint 3 - 48 hrs (AzaSite and Vigamox)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="559.733" spread="1011.658"/>
                    <measurement group_id="O2" value="1.129" spread="1.1673"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Timepoint 4 - 49 hrs (AzaSite and Vigamox)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="98.6" spread="4.535"/>
                    <measurement group_id="O2" value="15.754" spread="15.4107"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Timepoint 5 -72 hrs (AzaSite)/56 hrs (Vigamox)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="287.75" spread="433.4355"/>
                    <measurement group_id="O2" value=".862" spread=".6801"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Timepoint 6 - 144 hrs (AzaSite and Vigamox)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="175.017" spread="88.9250"/>
                    <measurement group_id="O2" value=".305" spread=".0917"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Timepoint 7 - 145 hrs (AzaSite and Vigamox)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="269.46" spread="316.2821"/>
                    <measurement group_id="O2" value="5.432" spread="4.0756"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Timepoint 8 - 168 hrs (AzaSite and Vigamox)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="261.125" spread="169.1224"/>
                    <measurement group_id="O2" value=".322" spread=".1792"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Timepoint 9 - 216 hrs (AzaSite and Vigamox)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="273.9" spread="160.4984"/>
                    <measurement group_id="O2" value=".165" spread=".1974"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Timepoint 10 - 312 (AzaSite and Vigamox)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="63.867" spread="51.1578"/>
                    <measurement group_id="O2" value=".011" spread=".0098"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Aqueous Humor Concentration Prior to Cataract Surgery at One of Ten Time Points Ranging From 1 to 14 Days (Per Protocol Pharmacokinetic Population)</title>
        <time_frame>Az(hr): 1,12,48,49,72,144,145,168,216,312; Vig(hr): 1,8,48,49,56,144,145,168,216,312</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Azasite</title>
          </group>
          <group group_id="O2">
            <title>Vigamox</title>
          </group>
        </group_list>
        <measure>
          <title>Aqueous Humor Concentration Prior to Cataract Surgery at One of Ten Time Points Ranging From 1 to 14 Days (Per Protocol Pharmacokinetic Population)</title>
          <units>ug/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="57"/>
                <count group_id="O2" value="55"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Timepoint 1- 1 hr (AzaSite and Vigamox)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value=".022" spread=".0297"/>
                    <measurement group_id="O2" value=".582" spread=".506"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Timepoint 2- 12 hrs (AzaSite)/ 8 hrs (Vigamox)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value=".088" spread=".0084"/>
                    <measurement group_id="O2" value=".113" spread=".0729"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Timepoint 3 - 48 hrs (AzaSite and Vigamox)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value=".047" spread=".0515"/>
                    <measurement group_id="O2" value=".079" spread=".0543"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Timepoint 4 - 49 hrs (AzaSite and Vigamox)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value=".023" spread=".0183"/>
                    <measurement group_id="O2" value=".765" spread=".5657"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Timepoint 5 - 72 hrs (AzaSite)/ 56 hr (Vigamox)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value=".02" spread=".0099"/>
                    <measurement group_id="O2" value=".084" spread=".0261"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Timepoint 6 - 144 hrs (AzaSite and Vigamox)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value=".026" spread=".0175"/>
                    <measurement group_id="O2" value=".225" spread=".1456"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Timepoint 7 - 145 hrs (AzaSite and Vigamox)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value=".052" spread=".0694"/>
                    <measurement group_id="O2" value=".669" spread=".402"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Timepoint 8 - 168 hrs (AzaSite and Vigamox)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value=".035" spread=".0276"/>
                    <measurement group_id="O2" value=".059" spread=".0265"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Timepoint 9 - 216 hrs (AzaSite and Vigamox)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value=".028" spread=".0353"/>
                    <measurement group_id="O2" value=".071" spread=".0845"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Timepoint 10 - 312 hrs (AzaSite and Vigamox)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value=".011" spread=".0102"/>
                    <measurement group_id="O2" value=".017" spread=".0189"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Azasite</title>
        </group>
        <group group_id="E2">
          <title>Vigamox</title>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="58"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 11.0</default_vocab>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="58"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="58"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Intraocular pressure increased</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="58"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="58"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>PI cannot publish or discuss trial results until written communication is received from Inspire</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Mike Schiewe</name_or_title>
      <organization>Inspire</organization>
      <phone>919-941-9777</phone>
      <email>mschiewe@inspirepharm.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

